Eflucimibe

CAS No. 202340-45-2

Eflucimibe( —— )

Catalog No. M34231 CAS No. 202340-45-2

Eflucimibe (L0081) is an acyl coenzyme A: cholesterol acyltransferase inhibitor for the treatment of cardiovascular disease and endocrine and metabolic disorders, and can be used to study atherosclerosis and hyperlipidemia.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 397 In Stock
5MG 376 In Stock
10MG 566 In Stock
25MG 905 In Stock
50MG 1200 In Stock
100MG 1646 In Stock
200MG 2223 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Eflucimibe
  • Note
    Research use only, not for human use.
  • Brief Description
    Eflucimibe (L0081) is an acyl coenzyme A: cholesterol acyltransferase inhibitor for the treatment of cardiovascular disease and endocrine and metabolic disorders, and can be used to study atherosclerosis and hyperlipidemia.
  • Description
    Eflucimibe (F 12511) is a new acyl-coenzyme A cholesterol O-acyltransferase (ACAT) inhibitor. Eflucimibe can be used in the research of atherosclerosis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Acyltransferase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    202340-45-2
  • Formula Weight
    469.72
  • Molecular Formula
    C29H43NO2S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    [C@H](C(NC1=C(C)C(C)=C(O)C(C)=C1)=O)(SCCCCCCCCCCCC)C2=CC=CC=C2
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Nathalie Mesplet, et al. Analysis of eflucimibe and related impurities by highly sensitive liquid chromatography-electrospray-tandem mass spectrometry. The Journal of Separation Science. 2003.
molnova catalog
related products
  • 12-Didecanoyl-sn-gly...

    12-Didecanoyl-sn-glycero-3-phosphocholi is a synthetic less hydrophobic phospholipid that has been found to be useful for enhancing the absorption of peptide drugs and hormones such as insulin.

  • pep2-EVKI

    Inhibitor peptide that selectively disrupts binding of the AMPA receptor subunit GluA2 (at the C-terminal PDZ site) to protein interacting with C kinase (PICK1). Does not affect binding of GluA2 to GRIP or ABP and does not increase AMPA current amplitude or affect long term depression (LTD).

  • Ezutromid

    The first orally bioavailable small molecule utrophin upregulator.